Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab Safety and Efficacy in Canadian CAPS Patients
NCT01105507Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2010
- Primary completion
- May 2012
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of canakinumab in Cryopyrin-associated periodic syndromes (CAPS), sponsored by Novartis. Primary endpoint: Safety & tolerability of canakinumab at 18 months. Started Aug 2010; status: completed.
02
Drugs
canakinumab
03
Conditions
Cryopyrin-associated periodic syndromes (CAPS)
Beyond the preview
Go deeper on NCT01105507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01105507.